Q3 2024 saw revenue and net profit decline sharply year-over-year, with most subsidiaries underperforming except Huakang Pharma. Cash flow and margins weakened, while management expenses and non-operating costs rose.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.